Bioquell has been transformed over the last 18 months, returning £40.8m to shareholders and completing investment in a range of proprietary bio-decontamination solutions focussing on the life sciences and healthcare market. A renewed focus on commercialisation and financial returns should lead to accelerated EPS growth and commensurate shareholder value creation. The strong balance sheet offers potential for further returns.
19 Oct 2016
N+1 Singer - Bioquell - A cleaner proposition
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Bioquell - A cleaner proposition
Bioquell (BQE:LON) | 0 0 (-1.6%) | Mkt Cap: 77.0m
- Published:
19 Oct 2016 -
Author:
Chris Glasper -
Pages:
16
Bioquell has been transformed over the last 18 months, returning £40.8m to shareholders and completing investment in a range of proprietary bio-decontamination solutions focussing on the life sciences and healthcare market. A renewed focus on commercialisation and financial returns should lead to accelerated EPS growth and commensurate shareholder value creation. The strong balance sheet offers potential for further returns.